Compare CCG & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCG | ICCC |
|---|---|---|
| Founded | 2014 | 1982 |
| Country | China | United States |
| Employees | 548 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.5M | 55.5M |
| IPO Year | N/A | 1995 |
| Metric | CCG | ICCC |
|---|---|---|
| Price | $0.79 | $6.11 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $350.00 | N/A |
| AVG Volume (30 Days) | ★ 60.6K | 12.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.80 | N/A |
| P/E Ratio | ★ N/A | $30.30 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.72 | $4.52 |
| 52 Week High | $1.54 | $7.60 |
| Indicator | CCG | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 38.92 |
| Support Level | $0.74 | $5.72 |
| Resistance Level | $0.82 | $6.90 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 74.83 | 7.14 |
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.